Gaudium IVF & Women Health Ltd.

As of June 30, 2026, Gaudium IVF & Women Health Ltd. carries a market capitalization of 8.23B, placing it among publicly traded companies globally. Its enterprise value stands at 8.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Gaudium IVF & Women Health Ltd. has 72.79M shares outstanding.

As of June 30, 2026, Gaudium IVF & Women Health Ltd. trades at a trailing price-to-earnings ratio of 33.99.

As of June 30, 2026, Gaudium IVF & Women Health Ltd. trades at an EV/EBITDA multiple of 23.38 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.76 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 25.29 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 8.23B versus a market cap of 8.23B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 8.69M in revenue per employee across its workforce of 122.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Gaudium IVF & Women Health Ltd. recorded 73.77M in income tax expense. That works out to an effective tax rate of 24.13, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 305.70M, leaving 231.91M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, Gaudium IVF & Women Health Ltd. generated 1.06B in revenue and converted that into 231.91M in net income, yielding earnings per share of 3.33. EBITDA reached 351.84M, while operating income came in at 325.22M.

Over the twelve months ended June 30, 2026, Gaudium IVF & Women Health Ltd. posted a gross margin of 51.48, reflecting its pricing power and cost economics. The operating margin of 30.69 and net profit margin of 21.88 provide insight into operational efficiency.